drugset / Trial / NCT01964183

Post-marketing Study to Evaluate the Effect of Mirabegron on the Plasma Concentration of Tolterodine

NCT01964183

Phase 4 Completed 24 enrolled Astellas Pharma Inc
NaSingle-groupOpen-label

Summary

To assess the effect of multiple doses of mirabegron to postmenopausal adult female subjects on the pharmacokinetics (PK) of tolterodine and its metabolites. In addition, the safety of these products will be assessed.

Timeline

Start
2013-06
Primary completion
2013-08
Completion
2013-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Mirabegron Other / unclassified Oral
Subject Tolterodine Small molecule Oral

Indications

No indication recorded.